文献速递胃肠动力与功能性疾病

经皮耳迷走神经刺激对便秘型肠易激综合征患者的疗效与安全性:单中心、单盲、随机对照试验

Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Constipation-Predominant Irritable Bowel Syndrome: A Single-Center, Single-Blind, Randomized Controlled Trial.
PubMed 文献 · Am J Gastroenterol · 2024-12-17

这项单中心、单盲、随机对照试验在安徽中国科学技术大学附属第一医院纳入40例便秘型肠易激综合征(IBS-C)患者,分为经皮耳迷走神经刺激(taVNS)组和假taVNS组各20例,完成4周干预。结果显示taVNS显著改善便秘和腹痛症状、精神心理评分及直肠感觉,并升高血清乙酰胆碱、降低一氧化氮,同时改变肠道菌群和代谢物。

要点

  • taVNS显著改善IBS-C患者的便秘和腹痛症状及生活质量,且不良事件可控。
  • taVNS改善直肠感觉阈值并调节自主神经功能,可能通过迷走-胆碱能和多组学机制起效。
  • taVNS升高双歧杆菌属及乙酸、丁酸、丙酸水平,降低部分色氨酸代谢物。

核心结论

  • 非侵入性taVNS有效改善IBS-C患者的便秘和腹痛症状,其症状缓解可能归因于taVNS对直肠功能的整合效应,由迷走、胆碱能和多组学机制介导。

研究设计与样本

  • 单中心、单盲、随机对照试验,在中国安徽中国科学技术大学附属第一医院执行。
  • 2023年9月至2024年5月期间,40例IBS-C患者完成4周研究,taVNS组和假taVNS组各20例,采用意向性分析。

主要发现

  • taVNS显著改善视觉模拟量表评分(P < 0.001)、IBS严重程度评分系统评分(P < 0.001)、每周自发排便频率(P < 0.001)、每周完全自发排便频率(P = 0.004)、Bristol粪便性状量表评分(P < 0.001)、汉密尔顿焦虑量表评分(P < 0.001)、汉密尔顿抑郁量表评分(P < 0.001)和IBS生活质量评分(P < 0.001)。
  • taVNS改善IBS-C患者的直肠感觉,包括初始感觉阈值容量(P = 0.033)、排便欲望阈值容量(P = 0.022)和直肠肛门抑制反射(P = 0.002)。
  • taVNS升高血清乙酰胆碱水平(P = 0.005)并降低一氧化氮水平(P = 0.016),同时通过心率变异性频谱分析增强迷走神经活动(P < 0.001)。
  • taVNS组3例和对照组2例出现不良后果,均可管理。
  • taVNS显著升高双歧杆菌属水平(P = 0.038)并增加乙酸(P = 0.003)、丁酸(P = 0.011)和丙酸(P = 0.005)水平,同时降低色氨酸代谢物含量,包括3-羟基邻氨基苯甲酸(P = 0.007)、邻氨基苯甲酸(P = 0.026)和L-色氨酸(P = 0.002)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Transcutaneous auricular vagus nerve stimulation (taVNS) is a promising therapy for irritable bowel syndrome (IBS). The aims of this clinical trial were to evaluate the influence of taVNS on autonomic functions, rectal sensation, and acetylcholine (Ach) levels and to explore potential mechanisms involving gut microbiota and metabolic profiles. METHODS: This study was a single-center, single-blind, randomized controlled trial executed at the First Affiliated Hospital of USTC, Anhui, China. Individual patients' constipation-predominant IBS (IBS-C)-related symptoms and mental health were assessed and scored using questionnaires at baseline and at week 4. Levels of serum Ach and nitric oxide, anorectal manometry, and heart rate variability were assessed both before and after the therapy. Fecal samples from each group were assessed to compare the gut microbiota, short-chain fatty acids, and gut microbiota-derived tryptophan metabolites. RESULTS: Between September 2023 and May 2024, 40 patients (n = 20 in both taVNS and sham-taVNS groups) completed the 4-week study by performing an intention-to-treat analysis. No differences in all parameters between taVNS and sham-taVNS groups at the baseline were found. The taVNS significantly improved the visual analog scale score ( P < 0.001), IBS Severity Scoring System score ( P < 0.001), weekly frequency of spontaneous bowel movements ( P < 0.001), weekly frequency of complete spontaneous bowel movements ( P = 0.004), Bristol Stool Form Scale score ( P < 0.001), Hamilton Anxiety Scale score ( P < 0.001), Hamilton Depression Scale score ( P < 0.001), and IBS Quality of Life score ( P < 0.001). Furthermore, taVNS improved rectal sensation in patients with IBS-C, including improvements in the threshold volume for initial sensation ( P = 0.033), urge to defecate ( P = 0.022), and rectoanal inhibitory reflex ( P = 0.002). Moreover, taVNS elevated serum levels of Ach ( P = 0.005) and reduced nitric oxide ( P = 0.016) while also enhancing vagal activity ( P < 0.001) as determined by spectral analysis of heart rate variability. Three patients in the taVNS group and 2 in the control group had adverse consequences, which were manageable. In addition, taVNS led to a significant rise in the level of the genus Bifidobacterium ( P = 0.038) and increased levels of acetic ( P = 0.003), butyric ( P = 0.011), and propionic ( P = 0.005) acids. It also decreased tryptophan metabolism content, including 3-hydroxyanthranilic acid ( P = 0.007), anthranilic acid ( P = 0.026), and L-tryptophan ( P = 0.002). DISCUSSION: The study manifested that noninvasive taVNS effectively improved constipation and abdominal pain symptoms in patients with IBS-C. The alleviation of IBS-C symptoms may be attributed to the integrative effects of taVNS on rectal functions, mediated through vagal, cholinergic, and multiomics mechanisms.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Liu J, Lv C, Yin M, et al. Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Constipation-Predominant Irritable Bowel Syndrome: A Single-Center, Single-Blind, Randomized Controlled Trial. Am J Gastroenterol. 2024. PMID: 39689011. doi:10.14309/ajg.0000000000003257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。